# TransCode Therapeutics Inc. (RNAZ)

Source: https://www.quantisnow.com/company/RNAZ
Generated: 2026-11-09T12:02:33.243Z

- Ticker: RNAZ
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2021
- SEC CIK: 0001829635

## Latest RNAZ news and filings

- 2026-10-28 20:35 UTC [SEC Form 8-K] [SEC Form 8-K filed by TransCode Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-transcode-therapeutics-inc-6761676)
- 2026-10-28 20:30 UTC [TransCode Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process Intended to Maximize Value of TTX-MC138 and its Oncology Portfolio](https://www.quantisnow.com/insight/transcode-therapeutics-retains-tungsten-advisors-to-lead-formal-strategic-process-6761604)
- 2026-10-26 11:31 UTC [TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026](https://www.quantisnow.com/insight/transcode-therapeutics-presents-phase-1a-clinical-data-for-ttx-mc138-at-6756962)
- 2026-10-19 12:04 UTC [TransCode Therapeutics to Present Phase 1a Clinical Trial Data for TTX-MC138 at ESMO Congress 2026](https://www.quantisnow.com/insight/transcode-therapeutics-to-present-phase-1a-clinical-trial-data-for-6750266)
- 2026-10-13 11:30 UTC [Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer](https://www.quantisnow.com/insight/natera-and-transcode-therapeutics-to-collaborate-on-phase-2a-trial-6744122)
- 2026-10-01 20:05 UTC [SEC Form 8-K] [TransCode Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Events That Accelerate or Increase a Direct Financial Obligation](https://www.quantisnow.com/insight/transcode-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6732369)
- 2026-09-28 12:16 UTC [SEC Form 8-K] [TransCode Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/transcode-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6727219)
- 2026-09-28 12:04 UTC [TransCode Reports Continued Disease Stabilization and Extended Treatment Duration with TTX-MC138 in Ongoing Phase 1a Clinical Trial Follow-Up](https://www.quantisnow.com/insight/transcode-reports-continued-disease-stabilization-and-extended-treatment-duration-with-6727192)
- 2026-09-22 12:04 UTC [TransCode Therapeutics Announces Patent Advancements in Australia and Japan Strengthening Global IP Position in RNA-Based Immuno-Oncology](https://www.quantisnow.com/insight/transcode-therapeutics-announces-patent-advancements-in-australia-and-japan-strengthening-6722454)
- 2026-09-21 21:42 UTC [SEC Form 3] [SEC Form 3 filed by new insider Tattory John A](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-tattory-john-a-6722036)
- 2026-09-11 21:10 UTC [SEC Form 4] [SEC Form 4 filed by Chief Financial Officer Fitzgerald Thomas A](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-financial-officer-fitzgerald-thomas-6713275)
- 2026-09-11 21:00 UTC [SEC Form 8-K] [TransCode Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/transcode-therapeutics-inc-filed-sec-form-8-k-leadership-update-financial-6713250)
- 2026-09-10 20:10 UTC [Public Offering] [TransCode Therapeutics Announces Leadership Transition](https://www.quantisnow.com/insight/transcode-therapeutics-announces-leadership-transition-6711613)
- 2026-08-31 12:05 UTC [TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis](https://www.quantisnow.com/insight/transcode-therapeutics-announces-publication-demonstrating-survival-benefit-of-ttx-mc138-in-6699183)
- 2026-08-14 21:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by TransCode Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-transcode-therapeutics-inc-6683628)
- 2026-08-05 20:05 UTC [SEC Form 4] [Large owner Defj, Llc converted options into 13,834,441 shares (SEC Form 4)](https://www.quantisnow.com/insight/large-owner-defj-llc-converted-options-into-13834441-shares-sec-6665087)
- 2026-08-05 20:05 UTC [SEC Form 3] [New insider Defj, Llc claimed ownership of 300,040 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-defj-llc-claimed-ownership-of-300040-shares-sec-6665056)
- 2026-08-03 20:38 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by TransCode Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-transcode-therapeutics-inc-6660155)
- 2026-08-03 20:15 UTC [SEC Form 8-K] [TransCode Therapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/transcode-therapeutics-inc-filed-sec-form-8-k-material-modification-to-6659871)
- 2026-07-28 23:51 UTC [SEC Form SCHEDULE 13G filed by TransCode Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-schedule-13g-filed-by-transcode-therapeutics-inc-6652233)
- 2026-07-27 20:15 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by TransCode Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-transcode-therapeutics-inc-6649724)
- 2026-07-23 20:15 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by TransCode Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-transcode-therapeutics-inc-6647154)
- 2026-07-20 21:06 UTC [SEC Form 424B3] [SEC Form 424B3 filed by TransCode Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-transcode-therapeutics-inc-6642735)
- 2026-07-20 21:04 UTC [SEC Form 424B3] [SEC Form 424B3 filed by TransCode Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-transcode-therapeutics-inc-6642725)
- 2026-07-20 20:15 UTC [SEC Form 8-K] [TransCode Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/transcode-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-6642519)
- 2026-07-17 20:15 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by TransCode Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-transcode-therapeutics-inc-6641102)
- 2026-07-17 20:08 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by TransCode Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-transcode-therapeutics-inc-6641010)
- 2026-07-17 20:05 UTC [SEC Form 8-K] [TransCode Therapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/transcode-therapeutics-inc-filed-sec-form-8-k-material-modification-to-6640990)
- 2026-07-02 20:05 UTC [SEC Form 8-K] [TransCode Therapeutics Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/transcode-therapeutics-inc-filed-sec-form-8-k-other-events-6625146)
- 2026-06-18 12:00 UTC [SEC Form 8-K] [TransCode Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/transcode-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6607952)
- 2026-06-08 12:04 UTC [TransCode Therapeutics to Host R&D Webcast on June 18, 2026](https://www.quantisnow.com/insight/transcode-therapeutics-to-host-rd-webcast-on-june-18-2026-6592649)
- 2026-06-03 12:08 UTC [SEC Form 8-K] [TransCode Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/transcode-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6585942)
- 2026-06-03 12:04 UTC [TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer](https://www.quantisnow.com/insight/transcode-therapeutics-successfully-completes-phase-1a-clinical-trial-reports-safety-6585911)
- 2026-06-02 20:05 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by TransCode Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-transcode-therapeutics-inc-6584096)
- 2026-06-01 12:59 UTC [SEC Form 8-K] [TransCode Therapeutics Inc. filed SEC Form 8-K: Shareholder Director Nominations](https://www.quantisnow.com/insight/transcode-therapeutics-inc-filed-sec-form-8-k-shareholder-director-nominations-6580957)
- 2026-05-27 12:04 UTC [TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer](https://www.quantisnow.com/insight/transcode-therapeutics-initiates-phase-2a-clinical-trial-with-ttx-mc138-in-6573926)
- 2026-05-26 10:46 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by TransCode Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-transcode-therapeutics-inc-6571139)
- 2026-05-26 10:43 UTC [SEC Form 8-K] [Amendment: TransCode Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/amendment-transcode-therapeutics-inc-filed-sec-form-8-k-notice-of-6571129)
- 2026-05-22 20:15 UTC [SEC Form 8-K] [TransCode Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/transcode-therapeutics-inc-filed-sec-form-8-k-notice-of-delisting-6569874)
- 2026-05-20 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by TransCode Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-transcode-therapeutics-inc-6564143)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/RNAZ
- Earnings history: https://www.quantisnow.com/earnings/RNAZ
- Dividend history: https://www.quantisnow.com/dividends/RNAZ
- Insider transactions: https://www.quantisnow.com/insiders/RNAZ
- Options chain: https://www.quantisnow.com/options/RNAZ
- SEC 8-K filings only: https://www.quantisnow.com/company/RNAZ/8-k
- RSS and alerts for RNAZ: https://www.quantisnow.com/docs/rss-feeds.md